In this article, Sino Biological discusses the necessity of developing new research reagents and new immunodiagnostics for the returning Monkeypox virus.
In this article, Sino Biological discusses targeting myeloid-derived suppressor cells in the tumor microenvironment to improve the efficacy of tumor immunotherapy.
In this interview, News-Medical talks to Dr. Lin Yutao, head of project management at Sino Biological,
about the work she does and how Sino provides quick and efficient recombinant CRO services.
Sino Biological, Inc. (https://www.sinobiological.com; SHE: 301047) announced today that it has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus